Skip to main content

Table 2 Patients characteristics in relation to p38 MAPK and p-p38 MAPK expressions

From: P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma

Features

p-p38+ (n = 24), n (%)

p-p38- (n = 56), n (%)

p38+ (n = 66), n (%)

p38- (n = 14), n (%)

p

Sex:

     

 Male

16 (64)

29 (52)

40 (61)

6 (42)

1.0

 Female

8 (36)

27 (48)

26 (39)

8 (58)

 

Age: Media, range

55, 30–65

60, 25–72

46, 20–68

53,15–75

0.74

Stage:

     

 1–2

8 (33)

20 (36)

22 (33)

6 (43)

0.26

 3–4

16 (67)

36 (64)

44 (67)

8 (57)

0.44

LDH:

     

 Normal

15 (50)

27 (33)

30 (39)

12 (29)

0.38

 High

9 (50)

29 (67)

36 (61)

2 (71)

0.33

IPI

     

 0–2

19 (33)

38 (50)

47 (44)

10 (43)

0.31

 3–5

5 (67)

18 (50)

19 (56)

4 (57)

0.51

PS > 1

*8 (33)

*5 (9)

*17 (26)

*1 (7)

* < 0.01

Bcl-2

     

 Positive

*24 (100)

*6 (10)

29 (45)

7 (50)

*0.003

 Negative

*0 (0)

*50 (90)

37 (55)

7(50)

*0.007

GC type

‘2 (8)

*56 (100)

*44 (66)

*14 (100)

* < 0.05

ABC

*22 (92)

*0 (0)

*22 (34)

*0 (0)

* < 0.01

NF-kB

     

 Positive

13 (54)

26 (46)

26 (40)

6 (42)

0.82

 Negative

11 (46)

30 (54)

40 (60)

8 (57)

0.96

  1. IPI International Prognostic Index, LDH Lactate Dehydrogenase, PS Performance status, GC germinal Center, ABC Activated B-Cell